Page last updated: 2024-11-12

d13-9001

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

D13-9001: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	17757337
CHEMBL ID	394052
MeSH ID	M0517455

Synonyms (8)

Synonym
CHEMBL394052
[{2-[({[(3r)-1-{8-[(4-tert-butyl-1,3-thiazol-2-yl)carbamoyl]-4-oxo-3-[(e)-2-(1h-tetrazol-5-yl)ethenyl]-4h-pyrido[1,2-a]pyrimidin-2-yl}piperidin-3-yl]oxy}carbonyl)amino]ethyl}(dimethyl)ammonio]acetate
d13-9001
Q27464316
CS-0087804
HY-124819
2-[2-[[(3r)-1-[8-[(4-tert-butyl-1,3-thiazol-2-yl)carbamoyl]-4-oxo-3-[(e)-2-(2h-tetrazol-5-yl)ethenyl]pyrido[1,2-a]pyrimidin-2-yl]piperidin-3-yl]oxycarbonylamino]ethyl-dimethylazaniumyl]acetate
AKOS040732911

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (35)

Assay ID	Title	Year	Journal	Article
AID309785	Half life in Sprague-Dawley rat at 20 mg/kg, iv	2007	Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22	MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 7: highly soluble and in vivo active quaternary ammonium analogue D13-9001, a potential preclinical candidate.
AID309775	Mean residential time (0 to infinity) in Sprague-Dawley rat at 5 mg/kg, iv	2007	Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22	MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 7: highly soluble and in vivo active quaternary ammonium analogue D13-9001, a potential preclinical candidate.
AID309774	Mean residential time (0 to infinity) in Sprague-Dawley rat at 1.25 mg/kg, iv	2007	Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22	MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 7: highly soluble and in vivo active quaternary ammonium analogue D13-9001, a potential preclinical candidate.
AID309772	AUC (0 to infinity) in Sprague-Dawley rat at 5 mg/kg, iv	2007	Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22	MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 7: highly soluble and in vivo active quaternary ammonium analogue D13-9001, a potential preclinical candidate.
AID309778	Clearance (0 to infinity) in Sprague-Dawley rat at 5 mg/kg, iv	2007	Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22	MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 7: highly soluble and in vivo active quaternary ammonium analogue D13-9001, a potential preclinical candidate.
AID309796	Half life in cynomolgus monkey at 1 mg/kg, iv	2007	Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22	MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 7: highly soluble and in vivo active quaternary ammonium analogue D13-9001, a potential preclinical candidate.
AID309764	Aqueous solubility at pH 6.8	2007	Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22	MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 7: highly soluble and in vivo active quaternary ammonium analogue D13-9001, a potential preclinical candidate.
AID309787	Drug level in cynomolgus monkey serum at 5 mg/kg, iv after 1 hr	2007	Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22	MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 7: highly soluble and in vivo active quaternary ammonium analogue D13-9001, a potential preclinical candidate.
AID309769	Drug level in Sprague-Dawley rat serum at 5 mg/kg, iv after 2 hrs	2007	Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22	MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 7: highly soluble and in vivo active quaternary ammonium analogue D13-9001, a potential preclinical candidate.
AID309788	AUC (0 to infinity) in cynomolgus monkey at 1 mg/kg, iv	2007	Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22	MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 7: highly soluble and in vivo active quaternary ammonium analogue D13-9001, a potential preclinical candidate.
AID309773	AUC (0 to infinity) in Sprague-Dawley rat at 20 mg/kg, iv	2007	Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22	MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 7: highly soluble and in vivo active quaternary ammonium analogue D13-9001, a potential preclinical candidate.
AID309771	AUC (0 to infinity) in Sprague-Dawley rat at 1.25 mg/kg, iv	2007	Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22	MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 7: highly soluble and in vivo active quaternary ammonium analogue D13-9001, a potential preclinical candidate.
AID309770	Drug level in Sprague-Dawley rat serum at 20 mg/kg, iv after 2 hrs	2007	Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22	MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 7: highly soluble and in vivo active quaternary ammonium analogue D13-9001, a potential preclinical candidate.
AID309766	Toxicity in mouse assessed as lethal effect at 100 mg/kg, iv	2007	Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22	MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 7: highly soluble and in vivo active quaternary ammonium analogue D13-9001, a potential preclinical candidate.
AID309792	Clearance (0 to infinity) in cynomolgus monkey at 1 mg/kg, iv	2007	Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22	MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 7: highly soluble and in vivo active quaternary ammonium analogue D13-9001, a potential preclinical candidate.
AID309780	Volume of distribution at steady state (0 to infinity) in Sprague-Dawley rat at 1.25 mg/kg, iv	2007	Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22	MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 7: highly soluble and in vivo active quaternary ammonium analogue D13-9001, a potential preclinical candidate.
AID309791	Mean residential time (0 to infinity) in cynomolgus monkey at 5 mg/kg, iv	2007	Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22	MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 7: highly soluble and in vivo active quaternary ammonium analogue D13-9001, a potential preclinical candidate.
AID309789	AUC (0 to infinity) in cynomolgus monkey at 5 mg/kg, iv	2007	Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22	MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 7: highly soluble and in vivo active quaternary ammonium analogue D13-9001, a potential preclinical candidate.
AID309768	Drug level in Sprague-Dawley rat serum at 1.25 mg/kg, iv after 2 hrs	2007	Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22	MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 7: highly soluble and in vivo active quaternary ammonium analogue D13-9001, a potential preclinical candidate.
AID309781	Volume of distribution at steady state (0 to infinity) in Sprague-Dawley rat at 5 mg/kg, iv	2007	Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22	MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 7: highly soluble and in vivo active quaternary ammonium analogue D13-9001, a potential preclinical candidate.
AID309784	Half life in Sprague-Dawley rat at 5 mg/kg, iv	2007	Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22	MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 7: highly soluble and in vivo active quaternary ammonium analogue D13-9001, a potential preclinical candidate.
AID309786	Drug level in cynomolgus monkey serum at 1 mg/kg, iv after 1 hr	2007	Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22	MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 7: highly soluble and in vivo active quaternary ammonium analogue D13-9001, a potential preclinical candidate.
AID309790	Mean residential time (0 to infinity) in cynomolgus monkey at 1 mg/kg, iv	2007	Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22	MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 7: highly soluble and in vivo active quaternary ammonium analogue D13-9001, a potential preclinical candidate.
AID309793	Clearance (0 to infinity) in cynomolgus monkey at 5 mg/kg, iv	2007	Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22	MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 7: highly soluble and in vivo active quaternary ammonium analogue D13-9001, a potential preclinical candidate.
AID309762	Inhibition of Pseudomonas aeruginosa PAM1723 MexAB-OprM assessed as drug level required to decrease MIC of levofloxacin in presence of 0.125% HAS	2007	Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22	MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 7: highly soluble and in vivo active quaternary ammonium analogue D13-9001, a potential preclinical candidate.
AID309761	Inhibition of Pseudomonas aeruginosa PAM1723 MexAB-OprM assessed as drug level required to decrease MIC of levofloxacin	2007	Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22	MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 7: highly soluble and in vivo active quaternary ammonium analogue D13-9001, a potential preclinical candidate.
AID309763	Inhibition of Pseudomonas aeruginosa PAM1723 MexAB-OprM assessed as drug level required to decrease MIC of aztreonam	2007	Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22	MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 7: highly soluble and in vivo active quaternary ammonium analogue D13-9001, a potential preclinical candidate.
AID309776	Mean residential time (0 to infinity) in Sprague-Dawley rat at 20 mg/kg, iv	2007	Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22	MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 7: highly soluble and in vivo active quaternary ammonium analogue D13-9001, a potential preclinical candidate.
AID309797	Half life in cynomolgus monkey at 5 mg/kg, iv	2007	Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22	MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 7: highly soluble and in vivo active quaternary ammonium analogue D13-9001, a potential preclinical candidate.
AID309794	Volume of distribution at steady state (0 to infinity) in cynomolgus monkey at 1 mg/kg, iv	2007	Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22	MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 7: highly soluble and in vivo active quaternary ammonium analogue D13-9001, a potential preclinical candidate.
AID309777	Clearance (0 to infinity) in Sprague-Dawley rat at 1.25 mg/kg, iv	2007	Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22	MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 7: highly soluble and in vivo active quaternary ammonium analogue D13-9001, a potential preclinical candidate.
AID309795	Volume of distribution at steady state (0 to infinity) in cynomolgus monkey at 5 mg/kg, iv	2007	Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22	MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 7: highly soluble and in vivo active quaternary ammonium analogue D13-9001, a potential preclinical candidate.
AID309779	Clearance (0 to infinity) in Sprague-Dawley rat at 20 mg/kg, iv	2007	Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22	MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 7: highly soluble and in vivo active quaternary ammonium analogue D13-9001, a potential preclinical candidate.
AID309782	Volume of distribution at steady state (0 to infinity) in Sprague-Dawley rat at 20 mg/kg, iv	2007	Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22	MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 7: highly soluble and in vivo active quaternary ammonium analogue D13-9001, a potential preclinical candidate.
AID309783	Half life in Sprague-Dawley rat at 1.25 mg/kg, iv	2007	Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22	MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 7: highly soluble and in vivo active quaternary ammonium analogue D13-9001, a potential preclinical candidate.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (40.00)	29.6817
2010's	2 (40.00)	24.3611
2020's	1 (20.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.84

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	12.84 (24.57)
Research Supply Index	1.79 (2.92)
Research Growth Index	4.63 (4.65)
Search Engine Demand Index	0.00 (26.88)
Search Engine Supply Index	0.00 (0.95)

This Compound (12.84)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	5 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
ljc 10627 biapenem: structure given in first source. biapenem : A carbapenem antibiotic in which the azetidine and pyrroline rings carry 1-hydroxymethyl and pyrazolo[1,2-a][1,2,4]triazolium-6-ylthio substituents respectively.	2.21	1	carbapenems; organic sulfide; pyrazolotriazole	antibacterial drug
imipenem, anhydrous Imipenem: Semisynthetic thienamycin that has a wide spectrum of antibacterial activity against gram-negative and gram-positive aerobic and anaerobic bacteria, including many multiresistant strains. It is stable to beta-lactamases. Clinical studies have demonstrated high efficacy in the treatment of infections of various body systems. Its effectiveness is enhanced when it is administered in combination with CILASTATIN, a renal dipeptidase inhibitor.. imipenem : A broad-spectrum, intravenous beta-lactam antibiotic of the carbapenem subgroup.	2.21	1	beta-lactam antibiotic allergen; carbapenems; zwitterion	antibacterial drug
tazobactam Tazobactam: A penicillanic acid and sulfone derivative and potent BETA-LACTAMASE inhibitor that enhances the activity of other anti-bacterial agents against beta-lactamase producing bacteria.. tazobactam : A member of the class of penicillanic acids that is sulbactam in which one of the exocyclic methyl hydrogens is replaced by a 1,2,3-triazol-1-yl group; used (in the form of its sodium salt) in combination with ceftolozane sulfate for treatment of complicated intra-abdominal infections and complicated urinary tract infections.	2.21	1	penicillanic acids; triazoles	antiinfective agent; antimicrobial agent; EC 3.5.2.6 (beta-lactamase) inhibitor
beta-lactams 2-azetidinone: structure in first source. azetidin-2-one : An unsubstituted beta-lactam compound.. beta-lactam : A lactam in which the amide bond is contained within a four-membered ring, which includes the amide nitrogen and the carbonyl carbon.	2.21	1	beta-lactam antibiotic allergen; beta-lactam
phenylalanine arginine beta-naphthylamide phenylalanine arginine beta-naphthylamide: a drug efflux pump inhibitor; structure in first source	2.05	1	peptide
aztreonam [no description available]	2.03	1	beta-lactam antibiotic allergen; monobactam	antibacterial drug; drug allergen; EC 2.4.1.129 (peptidoglycan glycosyltransferase) inhibitor
piperidines Piperidines: A family of hexahydropyridines.	3.2	5

Condition	Relationship Strength	Studies
Adverse Drug Event [description not available]	2.03	1
Infections, Pseudomonas [description not available]	2.03	1
Pseudomonas Infections Infections with bacteria of the genus PSEUDOMONAS.	2.03	1
Drug-Related Side Effects and Adverse Reactions Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.	2.03	1

chemdatabank.com